A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma Journal Article

  

Authors:	O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
Article Title:	A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
Abstract:	The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma. © 2008 The Authors.
Keywords:	adult; cancer chemotherapy; clinical article; treatment outcome; aged; aged, 80 and over; middle aged; fludarabine; prednisone; thalidomide; clinical trial; constipation; fatigue; neutropenia; doxorubicin; diarrhea; drug dose reduction; drug efficacy; monotherapy; antineoplastic agents; methotrexate; rituximab; carboplatin; bortezomib; mantle cell lymphoma; multiple cycle treatment; neutrophil count; phase 2 clinical trial; bone marrow suppression; etoposide; leukopenia; neuropathy; thrombocytopenia; drug administration schedule; recurrence; combination chemotherapy; alkylating agent; cyclophosphamide; dexamethasone; vincristine; ifosfamide; procarbazine; febrile neutropenia; lymphocytopenia; gastrointestinal toxicity; prednisolone; vincristine sulfate; nonhodgkin lymphoma; cancer vaccine; drug mechanism; lymphoma, non-hodgkin; multicenter study; motor neurons; sensory receptor cells; mitoxantrone; lymphoma; thrombocyte count; remission induction; cancer relapse; electromyography; maximum tolerated dose; tositumomab i 131; lymphoma, follicular; pralatrexate; chlorambucil; pentostatin; ixabepilone; epothilones; epothilone derivative; lymphoma, mantle-cell; cladribine; peginterferon; neural conduction; indolent non-hodgkin lymphoma
Journal Title:	British Journal of Haematology
Volume:	143
Issue:	2
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2008-10-01
Start Page:	201
End Page:	209
Language:	English
DOI:	10.1111/j.1365-2141.2008.07271.x
PUBMED:	18691173
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-52649085233&partnerID=40&md5=27a5e3b3e39d6d3d491233bad9775cc4
Notes:	--- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: BJHEA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/15050